Vol. 4 No. 12 (2024): December
Reimbursement Reviews

Etrasimod (Velsipity)

decorative image of the issue cover

Published December 3, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses etrasimod (Velsipity), 2 mg film-coated tablet.
  • Indication: The treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or an advanced treatment.